Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Review article: tegaserod -- the global experience.

W D Chey1

  • 1Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109-0362, USA. wchey@umich.edu

Alimentary Pharmacology & Therapeutics
|November 4, 2004
PubMed
Summary

Tegaserod is effective and safe for women with irritable bowel syndrome and constipation. Recent global studies confirm its benefits and enhance understanding of its role in treating this condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea.

Neurogastroenterology and motility·2018
Same author

Editorial: recurrence of Helicobacter pylori infection-still the same after all these years….

Alimentary pharmacology & therapeutics·2017
Same author

Development and validation of the Patient-Physician Relationship Scale among patients with irritable bowel syndrome.

Neurogastroenterology and motility·2017
Same author

Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.

Alimentary pharmacology & therapeutics·2017
Same author

Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.

Alimentary pharmacology & therapeutics·2016
Same author

Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.

Alimentary pharmacology & therapeutics·2014

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Irritable bowel syndrome with constipation (IBS-C) is a prevalent gastrointestinal disorder.
  • Tegaserod has demonstrated efficacy and safety in Western hemisphere studies for IBS-C management.

Purpose of the Study:

  • To review recent global studies on tegaserod for IBS-C.
  • To confirm the established efficacy and safety of tegaserod.
  • To expand the understanding of tegaserod's therapeutic role.

Main Methods:

  • Systematic review of recent international clinical studies.
  • Analysis of efficacy and safety data from tegaserod treatment trials.

Main Results:

  • Recent global studies corroborate the efficacy of tegaserod in treating IBS-C.
  • Safety profile of tegaserod is confirmed across diverse patient populations.
  • Evidence supports tegaserod's role in improving IBS-C symptoms.

Conclusions:

  • Tegaserod is a safe and effective treatment option for IBS-C.
  • Global data reinforce tegaserod's utility in managing IBS-C.
  • Further research supports tegaserod's established role in gastroenterology.

Related Experiment Videos